ATE359813T1 - Verbesserte i mycoplasma hyopneumoniae /i bacterin vakzine - Google Patents

Verbesserte i mycoplasma hyopneumoniae /i bacterin vakzine

Info

Publication number
ATE359813T1
ATE359813T1 AT01990123T AT01990123T ATE359813T1 AT E359813 T1 ATE359813 T1 AT E359813T1 AT 01990123 T AT01990123 T AT 01990123T AT 01990123 T AT01990123 T AT 01990123T AT E359813 T1 ATE359813 T1 AT E359813T1
Authority
AT
Austria
Prior art keywords
improved
mycoplasma hyopneumoniae
bacterin vaccine
bacterin
vaccine
Prior art date
Application number
AT01990123T
Other languages
English (en)
Inventor
Hsien-Jue Steve Chu
Wumin Li
Zhichang Xu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22972978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE359813(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE359813T1 publication Critical patent/ATE359813T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0241Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/825Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT01990123T 2000-12-19 2001-12-11 Verbesserte i mycoplasma hyopneumoniae /i bacterin vakzine ATE359813T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25663700P 2000-12-19 2000-12-19

Publications (1)

Publication Number Publication Date
ATE359813T1 true ATE359813T1 (de) 2007-05-15

Family

ID=22972978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01990123T ATE359813T1 (de) 2000-12-19 2001-12-11 Verbesserte i mycoplasma hyopneumoniae /i bacterin vakzine

Country Status (27)

Country Link
US (4) US20020131980A1 (de)
EP (1) EP1343525B1 (de)
JP (2) JP5074656B2 (de)
KR (1) KR100874119B1 (de)
CN (1) CN1296095C (de)
AR (1) AR033410A1 (de)
AT (1) ATE359813T1 (de)
AU (2) AU2899302A (de)
BG (1) BG66213B1 (de)
BR (1) BRPI0116249B1 (de)
CY (1) CY1106669T1 (de)
CZ (1) CZ307075B6 (de)
DE (1) DE60127994T2 (de)
DK (1) DK1343525T3 (de)
ES (1) ES2283452T3 (de)
HR (1) HRP20030585B1 (de)
HU (1) HU227431B1 (de)
ME (1) ME00570A (de)
MX (1) MXPA03005357A (de)
MY (1) MY129765A (de)
NZ (1) NZ526904A (de)
PL (1) PL211174B1 (de)
PT (1) PT1343525E (de)
RS (1) RS51536B (de)
TW (1) TWI308872B (de)
WO (1) WO2002049666A2 (de)
ZA (1) ZA200305545B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
GB0400264D0 (en) * 2004-01-07 2004-02-11 Polytherics Ltd Complexes
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
DK3766518T3 (da) 2005-12-29 2026-04-13 Boehringer Ingelheim Animal Health Usa Inc Immunogen pcv2-sammensætning til mindskelse af kliniske symptomer hos grise
EP3868400A1 (de) 2005-12-29 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Multivalente immunogene pcv2-zusammensetzungen und verfahren zur herstellung solcher zusammensetzungen
EP2859900A1 (de) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Wirksames Verfahren zur Behandlung von Infektionen mit dem porcinen Circovirus und Lawsonia intracellularis
PT2094872T (pt) 2006-12-15 2017-04-27 Boehringer Ingelheim Vetmedica Inc Tratamento de porcos seropositivos para o anticorpo anti-pcv2 com antigénio de pcv2
EP1941903A1 (de) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxe und Behandlung von PRDC
EP1958644A1 (de) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Vorbeugung und Behandlung von subklinischer PCVD
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
EP2217271B1 (de) 2007-11-06 2016-05-04 Zoetis Services LLC Avirulenter adjuvierter lebendimpfstoff gegen mycoplasma hyopneumoniae
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Pcv2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
MX2010014078A (es) * 2008-06-25 2011-04-11 Braasch Biotech Llc Composiciones y metodos para inmunogenecidad mejorada de somatostatina.
WO2010132932A1 (en) * 2009-05-19 2010-11-25 Bioproperties Pty Ltd A temperature sensitive vaccine strain of mycoplasma hyopneumoniae and uses thereof
US9539209B2 (en) 2009-06-04 2017-01-10 National Institute Of Infectious Diseases Vaccine for mycoplasma infection
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物
UA107940C2 (en) * 2009-09-10 2015-03-10 Merial Ltd The vaccine composition that includes the saponin-containing adjuvant
US9555093B2 (en) 2010-04-30 2017-01-31 Temasek Life Sciences Laboratory Limited Universal vaccine against H5N1 lineages
US20150086587A1 (en) * 2012-03-28 2015-03-26 Kansas State University Research Foundation Vaccine adjuvant
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
CN103623400B (zh) * 2012-08-24 2016-08-17 普莱柯生物工程股份有限公司 抗猪支原体肺炎、传染性胸膜肺炎疫苗组合物及制备方法
MX361273B (es) 2012-12-28 2018-12-03 Boehringer Ingelheim Vetmedica Gmbh Metodo para obtener una vacuna de mycoplasma.
AU2013370982C9 (en) * 2012-12-28 2019-01-24 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
CN104338128B (zh) * 2013-07-31 2017-09-05 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
MX373884B (es) 2013-10-02 2020-03-26 Boehringer Ingelheim Animal Health Usa Inc Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.
CA3022006A1 (en) * 2016-05-11 2017-11-16 Phibro Animal Health Corporation A composition comprising antigens and a mucosal adjuvant and a method for using
BR112020011041A2 (pt) * 2017-12-04 2020-11-17 Intervet International B.V. vacina contra a doença de lyme canina
CN108324941A (zh) * 2018-04-03 2018-07-27 林淑卿 猪疾病疫苗用佐剂及其制备方法
CN117100851A (zh) * 2023-10-23 2023-11-24 成都依思康生物科技有限公司 一种佐剂、疫苗组合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3790665A (en) * 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPH0832637B2 (ja) * 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
EP0283085B1 (de) 1987-03-17 1992-11-11 Akzo N.V. Adjuvanzienmischung
DE3855807T2 (de) * 1987-11-03 1997-06-12 Syntex (U.S.A.) Inc., Palo Alto, Calif. Einen Tetra-Polyol enthaltendes Impfstoff-Adjuvans
US5240706A (en) * 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
ES2112274T5 (es) 1990-05-29 2006-03-01 Wyeth Holdings Corporation Vacuna contra la pneumonia en cerdos y metodo para la preparacion de la misma.
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5695769A (en) * 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
DK0669971T3 (da) 1991-11-15 2003-04-22 Pfizer Fremgangsmåde til fremstilling af Gram-negative bakterielle vacciner
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) * 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
JP3265095B2 (ja) * 1993-11-19 2002-03-11 本田技研工業株式会社 キャニスタ
PT968722E (pt) * 1994-05-10 2007-09-06 Wyeth Corp Vacina viva melhorada contra brsv.
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) * 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) * 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
KR100615109B1 (ko) * 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모렉셀라 카타르할리스의 uspa1, uspa2 항원
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6342231B1 (en) * 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
EP2027873B8 (de) * 2001-07-02 2015-11-11 Zoetis Services LLC Vakzination in einer Dosis mit Mycoplasma Hyopneumoniae
US20050220880A1 (en) * 2002-03-07 2005-10-06 Lewis Andrew L Drug carriers comprising amphiphilic block copolymers
ITMI20030269A1 (it) * 2003-02-14 2004-08-15 Advance Holdings Ltd Sale di cetilpiridino di un agente antiinfiammatorio
US8052762B1 (en) * 2010-09-02 2011-11-08 Kelly Van Gogh, LLC Compositions for dyeing keratin-containing fibers

Also Published As

Publication number Publication date
ME00570B (me) 2011-12-20
AR033410A1 (es) 2003-12-17
DE60127994T2 (de) 2008-01-17
EP1343525B1 (de) 2007-04-18
BG66213B1 (bg) 2012-05-31
BRPI0116249B1 (pt) 2016-06-14
MY129765A (en) 2007-04-30
US20120213816A1 (en) 2012-08-23
JP2009073855A (ja) 2009-04-09
HUP0400687A2 (hu) 2004-06-28
HK1056513A1 (en) 2004-02-20
KR20030065556A (ko) 2003-08-06
CZ20031721A3 (cs) 2004-04-14
DK1343525T3 (da) 2007-06-04
HRP20030585B1 (en) 2008-03-31
PL363220A1 (en) 2004-11-15
HU227431B1 (en) 2011-06-28
PL211174B1 (pl) 2012-04-30
ME00570A (en) 2011-12-20
US9238065B2 (en) 2016-01-19
DE60127994D1 (de) 2007-05-31
ES2283452T3 (es) 2007-11-01
KR100874119B1 (ko) 2008-12-15
HRP20030585A2 (en) 2005-06-30
BG107898A (bg) 2004-08-31
CY1106669T1 (el) 2012-05-23
US20070020296A1 (en) 2007-01-25
JP2004518655A (ja) 2004-06-24
WO2002049666A3 (en) 2003-02-06
US7666439B2 (en) 2010-02-23
NZ526904A (en) 2005-07-29
TWI308872B (en) 2009-04-21
AU2899302A (en) 2002-07-01
PT1343525E (pt) 2007-07-12
YU49303A (sh) 2006-08-17
AU2002228993B2 (en) 2006-06-29
CZ307075B6 (cs) 2018-01-03
US20020131980A1 (en) 2002-09-19
EP1343525A2 (de) 2003-09-17
JP5074656B2 (ja) 2012-11-14
CN1489472A (zh) 2004-04-14
US20100119471A1 (en) 2010-05-13
RS51536B (sr) 2011-06-30
BR0116249A (pt) 2004-03-02
WO2002049666A2 (en) 2002-06-27
MXPA03005357A (es) 2003-10-06
ZA200305545B (en) 2004-10-18
US8187588B2 (en) 2012-05-29
CN1296095C (zh) 2007-01-24
HUP0400687A3 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
DE60127994D1 (de) VERBESSERTE i MYCOPLASMA HYOPNEUMONIAE /i BACTERIN VAKZINE
AU2002228993A1 (en) Mycoplasma hyopneumoniae bacterin vaccine
NO20035762L (no) En-dose vaksinering med mykoplasma hyopneumoniae
DK1296715T3 (da) Multivalent vaccinesammensætning
NO20031483L (no) Vaksine
NO20024172D0 (no) Vaksine
NO20034683D0 (no) Intradermal vaksineinnretning
PL363005A1 (pl) Szczepionki
DK1946771T3 (da) Multivalent vaccinesammensætning
ATE346608T1 (de) Impstoff gegen streptococcus pneumoniae
CY2012030I2 (el) Πολυδυναμο εμβολιο προϊοντος συζευξης μηνιγγοκοκκικου πολυσακχαριδιου-πρωτεϊνης
NO20043018L (no) Streptococcus pneumoniae vaksine
DK1265633T3 (da) Vaccineadjuvans
DE10293048T1 (de) Neuer Impfstoff
NO20030423L (no) Temperatursensitiv levende vaksine mot Mycoplasma hyopneumoniae
DK1267899T3 (da) ssa-inaktiverede salmonellavacciner
AU2002335609A8 (en) Multivalent mycoplasma bacterin
NO20032086D0 (no) Adjuvant kombinasjonsformuleringer
HK1055994A (en) Temperature-sensitive live vaccine for mycoplasma hyopneumoniae
FI20001964A0 (fi) Kuumailmakone

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1343525

Country of ref document: EP